Pfizer, Starboard Value
Pfizer fight with Starboard heats up, hedge fund alleges executive pressure
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the U.S. drugmaker to investigate actions by its board, after two former executives backed out of its campaign against the company.
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
1don MSN
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...
Pfizer (PFE) faces renewed calls for change as Jeffrey Smith, CEO of Starboard Value makes his case for his activist stance ...
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback